Marker Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRKR research report →
Companywww.markertherapeutics.com
Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens.
- CEO
- Juan F. Vera
- IPO
- 2002
- Employees
- 5
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $15.22M
- P/E
- -2.50
- P/S
- 7.27
- P/B
- 1.97
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -99.47%
- Op Margin
- -589.95%
- Net Margin
- -520.35%
- ROE
- -0.00%
- ROIC
- -89.43%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-12,163,620 · -13.35%
- EPS
- $-0.79 · 33.61%
- Op Income
- $-12,890,426
- FCF YoY
- -110116528.98%
Performance & Tape
- 52W High
- $4.07
- 52W Low
- $0.81
- 50D MA
- $1.44
- 200D MA
- $1.31
- Beta
- 1.43
- Avg Volume
- 116.69K
Get TickerSpark's AI analysis on MRKR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 25 | Knobil Katharine | other | 137,330 |
| Nov 17, 25 | Knobil Katharine | other | 84,411 |
| Nov 17, 25 | Eansor Norman David | other | 137,330 |
| Nov 17, 25 | Eansor Norman David | other | 84,411 |
| Nov 17, 25 | ELMS STEVE | other | 137,330 |
| Nov 17, 25 | ELMS STEVE | other | 84,411 |
| Oct 31, 25 | Corzo Kathryn Penkus | other | 147,611 |
| Oct 31, 25 | Vera Juan | other | 250,000 |
| Oct 31, 25 | Corzo Kathryn Penkus | other | 0 |
| Feb 12, 25 | ELMS STEVE | other | 30,000 |
Our MRKR Coverage
We haven't published any research on MRKR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MRKR Report →